HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
HUTCHMED (China) Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$14.18+0.13 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
Share price
−$0.96 (−6.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
HUTCHMED (China) Ltd saw revenue fall 13.0% to $548.51M over fiscal 2025. Free cash flow was -$78.81M.
Revenue
$548.51M
-13.0% vs. a year earlier
Operating income
-$39.16M
FY2025
Free cash flow
-$78.81M
FY2025
EPS, diluted
$0.52
+1200.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 27.3
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $548.51M
- Net income
- $456.91M
- EPS, diluted
- $0.52
- Free cash flow
- -$78.81M
Thirteen years at a glance
Fiscal years 2013 to 2025, USD
Revenue
$548.51M-13.0% YoY
Gross profit
$212.16M-24.6% YoY
Operating income
-$39.16M
Net income
$456.91M+1111.0% YoY
EPS, diluted
$0.52+1200.0% YoY
Free cash flow
-$78.81M
Reported period